Compare SY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | CAPR |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 324.6M |
| IPO Year | 2019 | N/A |
| Metric | SY | CAPR |
|---|---|---|
| Price | $3.07 | $26.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $5.50 | ★ $37.75 |
| AVG Volume (30 Days) | 981.2K | ★ 5.8M |
| Earning Date | 11-17-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,132,009.00 | $11,130,509.00 |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $51.30 | $7,736.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.67 | $4.30 |
| 52 Week High | $6.28 | $40.37 |
| Indicator | SY | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 71.67 |
| Support Level | $2.79 | $4.30 |
| Resistance Level | $3.33 | $29.23 |
| Average True Range (ATR) | 0.19 | 3.27 |
| MACD | 0.02 | 1.67 |
| Stochastic Oscillator | 50.93 | 60.66 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.